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Background and aims 
We examined HbA1c and cardiovascular risk factors with a median follow-up of 44 
months therapy with dapagliflozin.  
Methods 
We undertook a clinical practice evaluation of 101 patients attending our clinic. 
Results 
Dapagliflozin resulted in a significant reduction in HbA1c 82.6 ±15.7 v 68.7 ±17.8 
mmol/mol.  
Conclusion 
Dapagliflozin maintains glycaemic control along with sustained improvements in 






1. Dapagliflozin provides effective glycaemic control over a median of 44 months 
without deterioration in renal function. 
2. Weight loss was maintained with therapy during the treatment period. 
3. This supports maintained benefits associated with dapagliflozin during follow-up 




Sodium glucose co-transporter 2 inhibitors (SGLT-2i) improve glycaemic control, 
blood pressure, weight, and the decline in the onset of chronic kidney disease, 
cardiovascular events and heart failure. SGLT-2i have beneficial effects in the 
clinical trial [1-3] and the real-world setting [4-6]. There is debate relating to the 
validity of cardiovascular outcome trials [7] and the real-world trials [8] to routine 
practice. We describe our real-life clinical experience of dapagliflozin in secondary 




The work was undertaken as a routine evaluation of clinical practice. A total of 101 
patients with a pre-existing clinical diagnosis of type 2 diabetes mellitus (T2DM) were 
identified from our local secondary care electronic database that had treatment with 
dapagliflozin and had at least three years of follow-up data. The aim was to examine 
HbA1c, weight, body mass index (BMI), blood pressure, serum lipids, serum 
creatinine and estimated glomerular filtration rate (eGFR) and the urinary albumin: 
creatinine ratio (UACR) during follow-up. 
 
Statistical Analysis  
Paired t-tests were used to compare HbA1c, weight, BMI, blood pressure, 
cholesterol, LDL-cholesterol, HDL-cholesterol, creatinine and eGFR. The mean and 
standard deviation were used to describe these variables. UACR and triglycerides 
did not have a normal distribution and are described with the median and 




Baseline Characteristics  
At baseline, the mean age was 61 ±10 years, HbA1c 82.6 ±15.7 mmol/mol, weight 
106 ±21 kg, BMI 37 ±7 kg/m2. The sample comprised of 101 patients (43 males, 58 
females) with a median duration of diabetes of 12 years (interquartile range 8-12) 
and a median duration of dapagliflozin treatment of 44 months (range 36-82).  
 
Prior to dapagliflozin, there was considerable treatment heterogeneity. As shown in 
figure 1, 35 patients received a combination of insulin with or without oral agents; 20 
patients were taking glucagon like peptide-1 receptor agonists (GLP-1RA) with or 
without oral agents; 11 patients received a combination of GLP-1RA and insulin (as 
two injections or as xultophy) with or without oral agents; and 35 patients received 
oral therapies alone. Oral therapies consisted of combinations of metformin, 
sulphonylurea and dipeptidyl peptidase-4 (DPP-4) inhibitors.  
 
Changes in clinical measures associated with dapagliflozin 
Improvements in glycaemic control and weight were observed at follow-up. As 
shown in table 1, mean HbA1c prior to dapagliflozin was 82.6 ±15.7 mmol/mol and 
68.7 ±17.8 mmol/mol following the addition of dapagliflozin (p<0.0001). The mean 
reduction in weight and BMI were -7 kg and -3 kg/m2 respectively (p<0.0001). No 
decline was observed in eGFR and UACR. Ten patients had an episode of an acute 
coronary syndrome.  
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We chose a priori to divide the sample by the mean baseline HbA1c (83 mmol/mol) 
to examine response status by HbA1c at 6 months. We observed a greater reduction 
in HbA1c in the higher HbA1c group (-22.9 mmol/mol compared to -5.5 mmol/mol). 
In those with a HbA1c >83 mmol/mol, the pre and post dapagliflozin HbA1c were 
95.6 ±9.6 and 72.7 ±19.6 mmol/mol respectively (p<0.001). In those with HbA1c ≤83 
mmol/mol, the pre and post dapagliflozin HbA1c were 70.7 ±9.5 and 65.2 ±15.1 
mmol/mol respectively (p=0.009). 
 
Changes related to baseline medication 
As shown in table 2, those who received a combination of insulin with or without oral 
agents at baseline had significant improvements in HbA1c (-10.6 mmol/mol, p=0.01), 
weight (-4.2 kg, p=0.007) and BMI (-2.4 kg/m2, p=0.025). The total daily insulin dose 
was unchanged. For the patients receiving a GLP-1RA with or without oral agents at 
baseline, significant improvements were observed in HbA1c (-17.8 mmol/mol, 
p<0.0001), weight (-3.2kg, p<0.0001) and BMI (-4.2 kg/m2, p<0.0001). For patients 
taking a combination of a GLP-1RA and insulin with or without oral agents there was 
a significant improvement in HbA1c (-20.7 mmol/mol, p<0.0001). In those receiving 
oral therapy, dapagliflozin was associated with significant reductions in HbA1c (-12.7 
mmol/mol, p<0.0001), weight (-8.2 kg, p<0.0001) and BMI (-3.4 kg/m2, p<0.0001). 
 
Discussion  
SGLT-2i improve HbA1c, weight, cardiovascular risk and renal outcomes [1-6]. We 
describe real-world experience in a complex group of secondary care patients 
receiving combinations of diabetes therapies. Beneficial effects were seen on 
HbA1c, weight, and BMI, and no reduction was observed in eGFR after a median of 
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44 months. Dapagliflozin was associated with a maintained greater reduction in 
glucose in those with a higher HbA1c. The reduction in HbA1c was also observed in 
all therapy groups. Of interest there was a greater reduction in weight and BMI in 
those patients who received a GLP-1RA. This is in line with real-world studies were 
patients received treatment with GLP-1RA and an SGLT2i for up to 6 months [9] and 
a meta-analysis where participants were treated for up to 1 year [10]. Within the 
sample 10/101 had evidence of an acute coronary syndrome during follow-up. There 
was no significant decline observed in renal function.  
 
This study provides further real-world data demonstrating maintained benefits of 
dapagliflozin. Within the real-world, the available literature reports benefits up to 18 
months [11] and within the clinical trials up to 4 years [12]. We acknowledge that this 
study is limited by examining a sample of secondary care patients with a small 
number at follow-up. Nevertheless, the data should reassure the clinician that 
SGLT2i maintain efficacy in a complex sample treated with many different diabetes 
therapies. Our results are consistent with the observation that there is 
generalisability in patients with type 2 diabetes for benefit from SGLT2i [13]. A recent 
study examined the different baseline characteristics of patients who were initiated 
on dapagliflozin and suggested that this may influence patient outcomes. Whilst we 
saw differences relating to weight and BMI in different therapy groups, the effect on 
HbA1c appeared to be consistent [8]. 
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HbA1c (mmol/mol) 82.6 (15.7) 68.7 (17.8) <0.0001 
HbA1c (%) 9.7 (1.4) 8.4 (1.6)  
Weight (kg) 106 (21) 99 (19) <0.0001 
BMI (kg/m2) 37 (7) 34 (7) <0.0001 
Systolic blood pressure (mmHg) 140 (18) 139 (20) 0.81 
Diastolic blood pressure (mmHg) 81 (10) 78 (9) 0.02 
Cholesterol (mmol/L) 4.5 (1.5) 4.0 (1.0) <0.0001 
LDL-cholesterol (mmol/L) 2.1 (1.0) 2.8 (0.8) 0.001 
HDL-cholesterol (mmol/L) 1.4 (0.9) 1.2 (0.3) 0.06 
Triglyceride (mmol/L) * 1.8 [1.3-2.6] 1.8 [1.3-2.7] 0.78 
Creatinine (µmol/L) 71 (15) 74 (19) 0.09 
eGFR (mL/min per 1.73 m2) 95 (22) 93 (24) 0.20 
Urine ACR (mg/mol) * 1.9 [0.8-7.3] 3.1 [1.2-7.9] 0.29 
UACR: Urine albumin: creatinine ratio. eGFR: estimated glomerular filtration rate. 
BMI: Body mass index. Mean and standard deviation shown for normal data and 
analysed by paired t-test. *The median and interquartile range represents with data 






Table 2: The impact of previous therapy on dapagliflozin response at 3 years 
follow-up 
Measurement Pre dapagliflozin Post dapagliflozin P value 
Patients previously using insulin (n=35) 
HbA1c (mmol/mol) 85.3 (14.1) 74.7 (21.1) 0.01 
HbA1c (%) 10 (1.3) 9.0 (1.9)  
Weight (kg) 100.9 (20.5) 96.7 (18.5) 0.007 
BMI (kg/m2) 34.9 (5.9) 32.5 (8.0) 0.025 
Insulin total daily dose (units) 72 (41) 74 (41) 0.42 
Patients previously using GLP-1 analogues (n=20) 
HbA1c (mmol/mol) 83.6 (16.0) 65.8 (15.5) <0.0001 
HbA1c (%) 9.8 (1.5) 8.2 (1.4)  
Weight (kg) 101.1 (17.9) 97.9 (17.0) <0.0001 
BMI (kg/m2) 37.8 (7.2) 33.6 (6.0) <0.0001 
Patients previously using GLP-1 analogues and insulin (n=11) 
HbA1c (mmol/mol) 85.9 (19.8) 65.2 (16.3) <0.0001 
HbA1c (%) 10.0 (1.8) 8.1 (1.5)  
Weight (kg) 110.8 (17.7) 111.1 (13.5) 0.91 
BMI (kg/m2) 37.1 (4.8) 37.4 (4.3) 0.77 
Patients previously on oral therapies/no therapy (n=35) 
HbA1c (mmol/mol) 78.3 (15.4) 65.6 (14.0) <0.0001 
HbA1c (%) 9.3 (1.4) 8.2 (1.3)  
Weight (kg) 106.1 (17.9) 97.9 (23.0) <0.0001 
BMI (kg/m2) 38.4 (8.3) 35.0 (7.6) <0.0001 
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BMI: Body mass index. Mean and standard deviation shown for normal data and 
analysed by paired t-test.  
 
 
Figure 1: Diabetes therapies used by patients in our cohort prior to the 
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